Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants. In addition, its drug candidates include IBP-1118 to prevent retinopathy of prematurity that causes blindness in premature babies; and IBP-1122, indicated to eliminate vancomycin resistant enterococci that cause antibiotic resistant hospital infections. The company was incorporated in 2011 and is based in Stockholm, Sweden.
Metrics to compare | IBTb | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIBTbPeersSector | |
---|---|---|---|---|
P/E Ratio | −5.4x | −3.7x | −0.5x | |
PEG Ratio | −0.90 | 0.19 | 0.00 | |
Price/Book | 4.4x | −1.9x | 2.6x | |
Price / LTM Sales | −683,001.0x | −378,712.8x | 3.3x | |
Upside (Analyst Target) | - | 0.0% | 45.1% | |
Fair Value Upside | Unlock | −44.3% | 7.4% | Unlock |